222 related articles for article (PubMed ID: 15731164)
1. Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor.
Zeng Y; Yokohira M; Saoo K; Takeuchi H; Chen Y; Yamakawa K; Matsuda Y; Kakehi Y; Imaida K
Carcinogenesis; 2005 Jun; 26(6):1109-16. PubMed ID: 15731164
[TBL] [Abstract][Full Text] [Related]
2. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model.
Raghow S; Hooshdaran MZ; Katiyar S; Steiner MS
Cancer Res; 2002 Mar; 62(5):1370-6. PubMed ID: 11888907
[TBL] [Abstract][Full Text] [Related]
3. Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model.
Cho YM; Takahashi S; Asamoto M; Suzuki S; Tang M; Shirai T
Prostate Cancer Prostatic Dis; 2007; 10(4):378-83. PubMed ID: 17457304
[TBL] [Abstract][Full Text] [Related]
4. Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent.
Asamoto M; Hokaiwado N; Cho YM; Takahashi S; Ikeda Y; Imaida K; Shirai T
Cancer Res; 2001 Jun; 61(12):4693-700. PubMed ID: 11406539
[TBL] [Abstract][Full Text] [Related]
5. The selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model.
Nam KT; Hahm KB; Oh SY; Yeo M; Han SU; Ahn B; Kim YB; Kang JS; Jang DD; Yang KH; Kim DY
Clin Cancer Res; 2004 Dec; 10(23):8105-13. PubMed ID: 15585646
[TBL] [Abstract][Full Text] [Related]
6. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
7. Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model.
Raghow S; Kuliyev E; Steakley M; Greenberg N; Steiner MS
Cancer Res; 2000 Aug; 60(15):4093-7. PubMed ID: 10945615
[TBL] [Abstract][Full Text] [Related]
8. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
9. Lack of significant modifying effect of arctiin on prostate carcinogenesis in probasin/SV40 T antigen transgenic rats.
Zeng Y; Yokohira M; Takeuchi H; Saoo K; Yamakawa K; Matsuda Y; Hosokawa K; Li JQ; Ikeda M; Imaida K
Cancer Lett; 2005 May; 222(2):145-51. PubMed ID: 15863263
[TBL] [Abstract][Full Text] [Related]
10. Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma.
Shappell SB; Olson SJ; Hannah SE; Manning S; Roberts RL; Masumori N; Jisaka M; Boeglin WE; Vader V; Dave DS; Shook MF; Thomas TZ; Funk CD; Brash AR; Matusik RJ
Cancer Res; 2003 May; 63(9):2256-67. PubMed ID: 12727848
[TBL] [Abstract][Full Text] [Related]
11. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
Narayanan BA; Reddy BS; Bosland MC; Nargi D; Horton L; Randolph C; Narayanan NK
Clin Cancer Res; 2007 Oct; 13(19):5965-73. PubMed ID: 17908994
[TBL] [Abstract][Full Text] [Related]
12. Nimesulide and melatonin in mammary carcinogenesis prevention in female Sprague-Dawley rats.
Kubatka P; Kalická K; Chamilová M; Ahlersová E; Ahlers I; Bojková B; Adámeková E
Neoplasma; 2002; 49(4):255-9. PubMed ID: 12382025
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 accelerates multistep prostate carcinogenesis in vivo.
Bruckheimer EM; Brisbay S; Johnson DJ; Gingrich JR; Greenberg N; McDonnell TJ
Oncogene; 2000 Nov; 19(46):5251-8. PubMed ID: 11077442
[TBL] [Abstract][Full Text] [Related]
14. A cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation phase of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters.
Furukawa F; Nishikawa A; Lee IS; Kanki K; Umemura T; Okazaki K; Kawamori T; Wakabayashi K; Hirose M
Int J Cancer; 2003 Apr; 104(3):269-73. PubMed ID: 12569549
[TBL] [Abstract][Full Text] [Related]
15. Age-dependent histopathological findings in the prostate of probasin/SV40 T antigen transgenic rats: lack of influence of carcinogen or testosterone treatment.
Cho YM; Takahashi S; Asamoto M; Suzuki S; Inaguma S; Hokaiwado N; Shirai T
Cancer Sci; 2003 Feb; 94(2):153-7. PubMed ID: 12708490
[TBL] [Abstract][Full Text] [Related]
16. Dietary zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats.
Fong LY; Zhang L; Jiang Y; Farber JL
J Natl Cancer Inst; 2005 Jan; 97(1):40-50. PubMed ID: 15632379
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo.
Adhami VM; Malik A; Zaman N; Sarfaraz S; Siddiqui IA; Syed DN; Afaq F; Pasha FS; Saleem M; Mukhtar H
Clin Cancer Res; 2007 Mar; 13(5):1611-9. PubMed ID: 17332308
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide.
Shiotani H; Denda A; Yamamoto K; Kitayama W; Endoh T; Sasaki Y; Tsutsumi N; Sugimura M; Konishi Y
Cancer Res; 2001 Feb; 61(4):1451-6. PubMed ID: 11245450
[TBL] [Abstract][Full Text] [Related]
19. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R
Cancer Res; 2001 Oct; 61(20):7449-55. PubMed ID: 11606379
[TBL] [Abstract][Full Text] [Related]
20. Resistance of prostate cancer cell lines to COX-2 inhibitor treatment.
Wagner M; Loos J; Weksler N; Gantner M; Corless CL; Barry JM; Beer TM; Garzotto M
Biochem Biophys Res Commun; 2005 Jul; 332(3):800-7. PubMed ID: 15907789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
